234 related articles for article (PubMed ID: 23586323)
21. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Finlayson K; Pennington AJ; Kelly JS
Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
[TBL] [Abstract][Full Text] [Related]
22. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
Zhang S; Zhou Z; Gong Q; Makielski JC; January CT
Circ Res; 1999 May; 84(9):989-98. PubMed ID: 10325236
[TBL] [Abstract][Full Text] [Related]
24. Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy.
Tanaka H; Takahashi Y; Hamaguchi S; Iida-Tanaka N; Oka T; Nishio M; Ohtsuki A; Namekata I
Biol Pharm Bull; 2014; 37(11):1826-30. PubMed ID: 25366487
[TBL] [Abstract][Full Text] [Related]
25. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
[TBL] [Abstract][Full Text] [Related]
26. Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.
Saxena P; Hortigon-Vinagre MP; Beyl S; Baburin I; Andranovits S; Iqbal SM; Costa A; IJzerman AP; Kügler P; Timin E; Smith GL; Hering S
Br J Pharmacol; 2017 Sep; 174(18):3081-3093. PubMed ID: 28681507
[TBL] [Abstract][Full Text] [Related]
27. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
28. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
29. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
[TBL] [Abstract][Full Text] [Related]
30. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
31. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
32. Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis.
Wu ZY; Yu DJ; Soong TW; Dawe GS; Bian JS
J Biol Chem; 2011 Jun; 286(25):22186-94. PubMed ID: 21525004
[TBL] [Abstract][Full Text] [Related]
33. Dofetilide block involves interactions with open and inactivated states of HERG channels.
Weerapura M; Hébert TE; Nattel S
Pflugers Arch; 2002 Feb; 443(4):520-31. PubMed ID: 11907818
[TBL] [Abstract][Full Text] [Related]
34. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Li P; Sun HF; Zhou PZ; Ma CY; Hu GY; Jiang HL; Li M; Liu H; Gao ZB
Acta Pharmacol Sin; 2012 Jun; 33(6):728-36. PubMed ID: 22609836
[TBL] [Abstract][Full Text] [Related]
36. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
37. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
38. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
39. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
40. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]